Revive is a clinical-stage company focused on commercializing treatments for Gout and orphan drug indications such as, Cystinuria, Wilson disease and Rett syndrome. Revive’s business model employs a lower risk drug development and commercial strategy by focusing on finding new uses of old drugs through drug repurposing with the objective of finding an appropriate partner or partners to bring the new use drug to the marketplace.
Revive Therapeutics Ltd. Announces Results for the Three Months Ended September 30, 2015
Revive Therapeutics Announces Listing on the OTCQB Market Exchange
Dr. Lee S. Simon Joins Revive Therapeutics as Senior Clinical and Regulatory Affairs Advisor
Revive Therapeutics Announces US FDA Grants Orphan Drug Designation for Bucillamine for the Treatment of Cystinuria
Revive Therapeutics Ltd. Announces Results for Fiscal Year Ended June 30, 2015